|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ELP6 |
Gene summary for ELP6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ELP6 | Gene ID | 54859 |
| Gene name | elongator acetyltransferase complex subunit 6 | |
| Gene Alias | C3orf75 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0002097 | UniProtAcc | Q0PNE2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54859 | ELP6 | LZE2T | Human | Esophagus | ESCC | 1.56e-02 | 4.67e-01 | 0.082 |
| 54859 | ELP6 | LZE4T | Human | Esophagus | ESCC | 5.52e-03 | 1.85e-01 | 0.0811 |
| 54859 | ELP6 | LZE7T | Human | Esophagus | ESCC | 8.77e-03 | 2.19e-01 | 0.0667 |
| 54859 | ELP6 | LZE24T | Human | Esophagus | ESCC | 4.80e-12 | 2.45e-01 | 0.0596 |
| 54859 | ELP6 | LZE21T | Human | Esophagus | ESCC | 1.88e-02 | 1.83e-01 | 0.0655 |
| 54859 | ELP6 | LZE6T | Human | Esophagus | ESCC | 1.66e-05 | 2.49e-01 | 0.0845 |
| 54859 | ELP6 | P1T-E | Human | Esophagus | ESCC | 6.11e-03 | 1.56e-01 | 0.0875 |
| 54859 | ELP6 | P2T-E | Human | Esophagus | ESCC | 4.25e-13 | 2.43e-01 | 0.1177 |
| 54859 | ELP6 | P4T-E | Human | Esophagus | ESCC | 2.49e-24 | 4.66e-01 | 0.1323 |
| 54859 | ELP6 | P5T-E | Human | Esophagus | ESCC | 5.79e-05 | 1.28e-01 | 0.1327 |
| 54859 | ELP6 | P8T-E | Human | Esophagus | ESCC | 1.06e-11 | 2.10e-01 | 0.0889 |
| 54859 | ELP6 | P9T-E | Human | Esophagus | ESCC | 1.22e-07 | 2.55e-01 | 0.1131 |
| 54859 | ELP6 | P10T-E | Human | Esophagus | ESCC | 2.16e-21 | 3.40e-01 | 0.116 |
| 54859 | ELP6 | P11T-E | Human | Esophagus | ESCC | 9.95e-06 | 2.61e-01 | 0.1426 |
| 54859 | ELP6 | P12T-E | Human | Esophagus | ESCC | 4.38e-21 | 4.10e-01 | 0.1122 |
| 54859 | ELP6 | P15T-E | Human | Esophagus | ESCC | 6.30e-13 | 2.05e-01 | 0.1149 |
| 54859 | ELP6 | P16T-E | Human | Esophagus | ESCC | 7.06e-21 | 3.34e-01 | 0.1153 |
| 54859 | ELP6 | P17T-E | Human | Esophagus | ESCC | 3.99e-03 | 2.97e-01 | 0.1278 |
| 54859 | ELP6 | P19T-E | Human | Esophagus | ESCC | 6.01e-08 | 4.71e-01 | 0.1662 |
| 54859 | ELP6 | P20T-E | Human | Esophagus | ESCC | 1.74e-08 | 1.73e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
| GO:00064002 | Esophagus | ESCC | tRNA modification | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
| GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
| GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:0008033 | Liver | HCC | tRNA processing | 87/7958 | 127/18723 | 2.66e-09 | 7.23e-08 | 87 |
| GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
| GO:0009451 | Liver | HCC | RNA modification | 101/7958 | 167/18723 | 2.02e-06 | 2.78e-05 | 101 |
| GO:0006400 | Liver | HCC | tRNA modification | 60/7958 | 90/18723 | 3.09e-06 | 4.09e-05 | 60 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:00080332 | Oral cavity | OSCC | tRNA processing | 78/7305 | 127/18723 | 2.56e-07 | 4.00e-06 | 78 |
| GO:00063991 | Oral cavity | OSCC | tRNA metabolic process | 101/7305 | 179/18723 | 1.65e-06 | 2.15e-05 | 101 |
| GO:00094511 | Oral cavity | OSCC | RNA modification | 95/7305 | 167/18723 | 2.05e-06 | 2.62e-05 | 95 |
| GO:00064001 | Oral cavity | OSCC | tRNA modification | 53/7305 | 90/18723 | 1.04e-04 | 7.70e-04 | 53 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ELP6 | SNV | Missense_Mutation | rs545060366 | c.54N>T | p.Gln18His | p.Q18H | Q0PNE2 | protein_coding | deleterious(0.01) | possibly_damaging(0.81) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
| ELP6 | SNV | Missense_Mutation | c.263N>G | p.Lys88Arg | p.K88R | Q0PNE2 | protein_coding | tolerated(0.24) | benign(0.058) | TCGA-E2-A1L9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| ELP6 | insertion | Frame_Shift_Ins | novel | c.217_218insTTTGTCCCAAAAGCTATAGAGAGGATCATTTGCTGGAAGGATGG | p.Thr73IlefsTer58 | p.T73Ifs*58 | Q0PNE2 | protein_coding | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| ELP6 | SNV | Missense_Mutation | c.773N>T | p.Ala258Val | p.A258V | Q0PNE2 | protein_coding | deleterious(0) | possibly_damaging(0.544) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| ELP6 | SNV | Missense_Mutation | c.294N>C | p.Gln98His | p.Q98H | Q0PNE2 | protein_coding | tolerated(0.08) | possibly_damaging(0.571) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ELP6 | SNV | Missense_Mutation | rs758926474 | c.706N>A | p.Ala236Thr | p.A236T | Q0PNE2 | protein_coding | tolerated(1) | benign(0) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ELP6 | SNV | Missense_Mutation | novel | c.703N>T | p.Pro235Ser | p.P235S | Q0PNE2 | protein_coding | tolerated(0.74) | benign(0.001) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ELP6 | SNV | Missense_Mutation | rs759438726 | c.280G>A | p.Val94Ile | p.V94I | Q0PNE2 | protein_coding | tolerated(0.21) | benign(0.013) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| ELP6 | SNV | Missense_Mutation | rs370492398 | c.626N>A | p.Arg209Gln | p.R209Q | Q0PNE2 | protein_coding | tolerated(0.38) | benign(0.121) | TCGA-AP-A05J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| ELP6 | SNV | Missense_Mutation | novel | c.201G>T | p.Lys67Asn | p.K67N | Q0PNE2 | protein_coding | deleterious(0) | possibly_damaging(0.756) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |